MAXCYTE INC (MXCT) Forecast, Price Target & Analyst Ratings
NASDAQ:MXCT • US57777K1060
0.7824 USD
-0.05 (-6.37%)
At close: Mar 6, 2026
0.8 USD
+0.02 (+2.25%)
After Hours: 3/6/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MAXCYTE INC (MXCT).
Forecast Snapshot
Consensus Price Target
$5.75
+ 635.54% Upside
Next Earnings Forecast
Release DateMar 24, 2026
PeriodQ4 / 2025
EPS Estimate-$0.08
Revenue Estimate9.586M
ChartMill Buy Consensus
83.08%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.75
Upside
+ 635.54%
From current price of $0.78 to mean target of $5.75, Based on 13 analyst forecasts
Low
$2.23
Median
$5.10
High
$9.45
Price Target Revisions
1 Month
-11.07%
3 Months
-11.07%
Price Target Summary
13 analysts have analysed MXCT and the average price target is 5.75 USD. This implies a price increase of 635.54% is expected in the next year compared to the current price of 0.7824.
The average price target has been revised downward by 11.07% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
83.08%
MXCT was analyzed by 13 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about MXCT.
In the previous month the buy percentage consensus was at a similar level.
MXCT was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-11 | BTIG | Downgrade | Buy -> Neutral |
| 2025-08-07 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-03-12 | Stifel | Maintains | Buy -> Buy |
| 2024-04-23 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-03-13 | BTIG | Maintains | Buy -> Buy |
| 2024-03-13 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2023-11-29 | Craig-Hallum | Initiate | Buy |
| 2023-10-05 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2023-03-28 | Stephens & Co. | Reiterate | Overweight |
| 2022-08-15 | BTIG | Maintains | Buy |
| 2021-08-24 | William Blair | Initiate | Outperform |
| 2021-08-24 | BTIG | Initiate | Buy |
| 2021-08-24 | Stephens & Co. | Initiate | Overweight |
| 2021-08-24 | Stifel | Initiate | Buy |
| 2021-08-24 | Cowen & Co. | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 24, 2026
PeriodQ4 / 2025
EPS Estimate-$0.08
Revenue Estimate9.586M
Revenue Q2Q10.27%
EPS Q2Q18.40%
Number of Analysts8
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-0.08%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
MXCT is expected to report earnings on 3/24/2026. The consensus EPS estimate for the next earnings is -0.08 USD and the consensus revenue estimate is 9.59M USD.
The next earnings revenue estimate has been revised downward by 0.08% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 44.26M 30.60% | 41.288M -6.71% | 38.627M -6.44% | 35.73M -7.50% | 39.173M 9.64% | 47.934M 22.36% | 69.809M 45.64% | 97.732M 40.00% | 146.6M 50.00% | 219.9M 50.00% | 307.86M 40.00% | |
| EBITDA YoY % growth | -24.66M -47.05% | -44.128M -78.95% | -46.882M -6.24% | -34.451M 26.52% | -27.476M 20.25% | -26.601M 3.18% | -22.44M 15.64% | -9.894M 55.91% | 4.896M 149.48% | N/A | N/A | |
| EBIT YoY % growth | -27.36M -50.41% | -48.299M -76.53% | -51.197M -6.00% | -50.076M 2.19% | -37.189M 25.74% | -29.153M 21.61% | -6.981M 76.05% | 9.774M 240.01% | 29.32M 199.98% | 54.974M 87.50% | 92.357M 68.00% | |
| Operating Margin | -61.82% | -116.98% | -132.54% | -140.15% | -94.93% | -60.82% | -10.00% | 10.00% | 20.00% | 25.00% | 30.00% | |
| EPS YoY % growth | -0.23 -17.44% | -0.37 -60.87% | -0.39 -5.41% | -0.41 -4.09% | -0.28 31.32% | -0.22 21.95% | -0.20 6.25% | -0.11 45.00% | 0.00 100.00% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 18.40% | -0.06 36.25% | -0.06 46.87% | -0.06 34.83% | -0.05 40.00% | -0.05 20.00% | -0.05 20.00% | -0.04 30.43% | -0.04 27.08% |
| Revenue Q2Q % growth | 9.586M 10.27% | 9.082M -12.59% | 9.127M 7.29% | 9.938M 45.53% | 11.579M 20.79% | 10.2M 12.31% | 10.608M 16.23% | 11.118M 11.87% | 12.954M 11.87% |
| EBITDA Q2Q % growth | -8.058M 6.15% | -7.832M 23.85% | -7.746M 35.62% | -7.397M 7.39% | -6.37M 20.95% | -8.058M -2.89% | -7.854M -1.40% | -7.548M -2.05% | -6.834M -7.28% |
| EBIT Q2Q % growth | -10.119M 21.57% | -9.343M 17.90% | -9.301M 34.62% | -8.824M 21.60% | -7.518M 25.70% | -9.486M -1.53% | -8.364M 10.08% | -7.446M 15.61% | -5.916M 21.31% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.98%
EPS Next 5 Year
11.36%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
7.45%
Revenue Next 5 Year
20.40%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
14.64%
EBIT Next 5 Year
12.68%
MAXCYTE INC / MXCT Forecast FAQ
What is the price target for MXCT stock?
13 analysts have analysed MXCT and the average price target is 5.75 USD. This implies a price increase of 635.54% is expected in the next year compared to the current price of 0.7824.
Can you provide the upcoming earnings date for MAXCYTE INC?
MAXCYTE INC (MXCT) will report earnings on 2026-03-24, after the market close.
What are the consensus estimates for MAXCYTE INC (MXCT) next earnings?
The consensus EPS estimate for the next earnings of MAXCYTE INC (MXCT) is -0.08 USD and the consensus revenue estimate is 9.59M USD.
How do analysts rate MAXCYTE INC (MXCT)?
The consensus rating for MAXCYTE INC (MXCT) is 83.0769 / 100 . This indicates that analysts generally have a positive outlook on the stock.